VolitionRx Announces Collaboration with Sysmex

Big promises, but little proof—wait for real deals before getting excited.

Risk flags

• ●Operational risk is high because the collaboration is at the optimization stage, not yet at commercialization or revenue generation. This means there are multiple technical and regulatory hurdles still to clear before any financial benefit can be realized.
• ●Financial risk is significant due to the complete absence of disclosed revenue, profit, or cash flow figures. Investors have no way to assess the company’s burn rate, funding needs, or ability to sustain operations until commercialization.
• ●Disclosure risk is acute: the announcement omits key details such as deal terms, upfront payments, milestones, or binding commitments. Without these, it is impossible to gauge the true depth or enforceability of the partnership.
• ●Pattern-based risk is present because the announcement relies heavily on forward-looking statements and market potential, with little evidence of past execution or realized milestones. This pattern is often associated with companies that over-promise and under-deliver.
• ●Timeline/execution risk is high, as the path from assay optimization to commercial sales is long and fraught with uncertainty. Delays in development, regulatory setbacks, or failure to secure licensing deals could push value realization years into the future.
• ●Geographic risk exists due to the multinational nature of the collaboration (Japan, Belgium, United States), which introduces complexity in regulatory approvals, market access, and operational coordination. Cross-border projects often face unforeseen delays and complications.
• ●Forward-looking risk is substantial: the majority of claims are aspirational and contingent on future events, such as successful commercialization and market adoption. If these do not materialize, the projected $3.8 billion opportunity will remain theoretical.
• ●Leadership risk is moderate: while the involvement of Gael Forterre, Chief Commercial Officer, signals executive attention, there is no mention of external institutional validation or third-party investment, which would provide stronger independent endorsement.

Bottom line

For investors, this announcement is more about potential than reality. The company is selling a vision of a lucrative partnership and a massive market opportunity, but provides no evidence of actual progress toward revenue or commercial adoption. The lack of financial disclosure—no revenue, no deal terms, no operational milestones—means that the narrative is not currently credible as a basis for investment. The involvement of senior management, such as the Chief Commercial Officer, is necessary but not sufficient to validate the opportunity; without external institutional participation or binding agreements, the partnership remains speculative. To change this assessment, the company would need to disclose signed, revenue-generating contracts, regulatory approvals, or concrete operational milestones achieved. In the next reporting period, investors should look for evidence of binding deals, regulatory progress, and actual sales or licensing revenue. Until such data is provided, this announcement should be weighted as a signal to monitor, not to act on. The most important takeaway is that the gap between promise and proof is wide—wait for hard evidence before making an investment decision.

Announcement summary

(NYSE: VNRX) VolitionRx Limited, a multi-national epigenetics company, announced a collaboration with Sysmex to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex platform. The commercial opportunity for the Nu.Q® NETs assay is significant, with a Total Addressable Market of $3.8 billion. Sysmex Corporation is headquartered in Kobe, Japan, and supports the health of people in over 190 countries and regions worldwide. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The collaboration aims to leverage Sysmex's knowledge of specific diseases, product development, regulatory experience, and their installed base of proprietary analyzers. Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company projects revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, and success in securing licensing and/or distribution agreements with third parties for its products.

Disagree with this article?